No­var­tis dives even deep­er in­to ra­di­oli­gands, notch­ing li­cens­ing deal with iTher­a­nos­tics for mul­ti­ple com­pounds

No­var­tis cap­tured at­ten­tion last week for its Phase III prostate can­cer win with a ra­di­oli­gand ther­a­py it picked up for $2 bil­lion back in 2018. Now, No­var­tis is dou­bling down on the field.

No­var­tis will ac­quire de­vel­op­ment and com­mer­cial rights to two iTher­a­nos­tics ra­di­oli­gand ther­a­pies tar­get­ing fi­brob­last ac­ti­va­tion pro­teins on the sur­face of tu­mor cells, the Swiss drug­mak­er said Tues­day. The deal cov­ers can­di­dates FAPI-46 and FAPI-74.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER